DVA

Business profile & competitive position

DaVita Inc. is classified under Healthcare, specifically the Medical - Care Facilities industry, and is a leading U.S. provider of kidney dialysis services and related laboratory services for patients with chronic kidney failure and end-stage kidney disease. As of December 31, 2025, the company operated 2,657 outpatient U.S. dialysis centers serving approximately 200,500 patients. It also ran 585 outpatient dialysis centers across 14 countries serving roughly 94,500 patients, plus integrated kidney care, ancillary services, home-based dialysis, and transplant support.

Scale is the most visible competitive asset here: a 2,657-center footprint creates negotiating leverage with commercial payors and operational density. The quality track record also matters; DaVita has been an industry leader in CMS’s Quality Incentive Program for the 11 most recently reported years and in the Five-Star Quality Rating System for the 10 most recently reported years. Still, the numbers suggest the moat is not a high-margin one. The net margin is 6.0%, which is thin, and the ROE is -123.6%. The negative ROE typically reflects a capital structure in which shareholders’ equity has been driven below zero by leverage or distributions rather than current operational losses, but it does show that scale and reputation have not translated into a straightforwardly profitable book-equity return.

Financial posture

DaVita currently carries a market capitalization of $12.1 billion and trades at a price-to-earnings ratio of 16.1. That multiple is relatively modest by growth-stock standards, which fits a mature, volume-based healthcare services business. The 6.0% net margin means the company keeps only a small slice of each revenue dollar after all expenses, so small changes in reimbursement or payer mix can have an outsized effect on earnings.

The most striking figure is the -123.6% ROE. Because net income is positive, the negative ROE signals that book shareholders’ equity is negative. In practice, that usually means debt, lease liabilities, or share buybacks have compressed equity below zero, not that the core dialysis operation is burning cash. The beta is 0.83, below the market average, indicating that the stock has historically moved less dramatically than the broad market outside of earnings events. Overall, the valuation reads like a profitable but highly leveraged, reimbursement-sensitive services company.

Strategic priorities & outlook

DaVita’s most recent 10-K filing lays out three operational priorities. First, the company wants to “reimagine high-quality kidney care” to be more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. Second, it is building integrated care capabilities across the renal care continuum, from chronic kidney disease through end-stage kidney disease to kidney transplant. Third, it is supporting the Comprehensive Kidney Care Contracting model goals of delaying disease progression, promoting home dialysis when appropriate, and incentivizing transplants.

The filing also underscores where the money comes from. U.S. dialysis represented approximately 86% of consolidated revenues, and nearly all non-hospital dialysis profits came from commercial payors. That makes commercial pricing a critical variable even though government programs account for a large share of treatments. International dialysis is a smaller but still meaningful footprint at 585 centers in 14 countries. The strategic direction is therefore clear: defend the core U.S. clinic network while pushing upstream into early-stage kidney disease management and downstream into transplant and home-based alternatives.

Macro & geopolitical exposure

A Medical - Care Facilities operator like DaVita sits at the intersection of healthcare policy, labor markets, and supply chains. Medicare and Medicaid reimbursement rates are central to revenue, because the dialysis patient population skews heavily toward government payors. Any changes to the End-Stage Renal Disease Prospective Payment System, the Medicare Physician Fee Schedule, or drug reimbursement policies can alter facility-level economics.

The company is also exposed to value-based care experiments such as the Comprehensive Kidney Care Contracting model, to commercial insurer negotiations, and to labor costs for nurses, technicians, and clinic staff. Supply-chain factors matter too: dialyzers, dialysis fluids, and other specialized equipment can be subject to tariff, import, or logistics disruption. Outside the U.S., the 14-country international footprint creates currency-translation exposure. On the demand side, an aging population with rising rates of diabetes and hypertension supports long-term utilization, but regulatory and reimbursement risks determine whether that volume turns into stable margin.

Recent developments

The most recent headlines from Zacks frame a stock that has been under pressure despite solid headline numbers. On August 28, 2026, Zacks published “4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds,” putting the dialysis and home-care sector on investors’ radar. On September 3, 2026, a Zacks article asked “Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?”—a drawdown explained by the August 4, 2026 report, when DaVita beat the $3.88 consensus with EPS of $4.02 but the stock still fell 17.24% the next day and 21.78% over the following five days.

The same day, September 3, 2026, Zacks ran “Do Options Traders Know Something About DaVita Stock We Don't?,” reflecting market confusion about the divergence between earnings performance and price action. A September 9, 2026, Zacks headline argued investors should “Retain DaVita Stock in Your Portfolio for Now.” The common thread is that DaVita’s recent narrative has been dominated by a “good numbers, bad reaction” pattern rather than by operational breakdown.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, DaVita has beaten earnings expectations six times, for a 75% beat rate, with an average earnings surprise of 2.3%. The average five-day price move after earnings across those quarters is +6.36%, which is classified as an upward drift. That top-line average, however, masks very divergent behavior from quarter to quarter.

Over the last four reports, the pattern looks binary. On May 5, 2026, DaVita reported actual EPS of $2.87 against an estimate of $2.41, a 19.1% surprise, and the stock jumped 23.46% the next day and 27.7% over the next five days. On February 2, 2026, actual EPS of $3.40 beat the $3.24 estimate by 4.9%, producing a 21.17% next-day gain and a 23.79% five-day gain. By contrast, the most recent quarter on August 4, 2026, was a 3.6% beat—actual EPS $4.02 versus estimate $3.88—but the stock fell 17.24% the next day and 21.78% over the following five days. The prior miss, on October 29, 2025, saw actual EPS of $2.51 versus $3.17, a -20.8% surprise, with the stock dropping 6.17% the next day and 4.27% over five days.

The takeaway is the notable pattern highlighted in the data: even on beat quarters, the post-earnings drift has not reliably continued in the direction of the surprise. The +6.36% average is carried by a couple of large rallies that were strong enough to offset the August collapse. The next report is scheduled for October 28, 2026, after the close, with a consensus EPS estimate of $3.58. At the current price of $187.80, the RSI is 51.7 and the 50-day EMA is $192.82.

For a deeper dive into DaVita, including the complete set of institutional ratings, price-target ranges, and sector-relative rankings, it is worth reviewing the full institutional verdict on the stock.